var data={"title":"Levocabastine (Nasal) (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levocabastine (Nasal) (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/433610?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levocabastine-nasal-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levocabastine (Nasal) (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231185\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Livostin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231189\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Histamine H<sub>1</sub> Antagonist;</li>\n      <li>\n        Histamine H<sub>1</sub> Antagonist, Second Generation;</li>\n      <li>\n        Piperidine Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231227\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Allergic rhinitis:</b> Adults &le;65 years: Intranasal: Two sprays in each nostril twice daily; if necessary, may increase dose to 2 sprays 3 to 4 times daily; consider therapy discontinuation if no response within 3 days. Continuous treatment &gt;10 weeks has not been evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990765\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987916\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231226\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Allergic rhinitis:</b> Children &ge;12 years and Adolescents: Intranasal: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231248\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the United States.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Microsuspension, intranasal, as hydrochloride [spray]:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Livostin: 0.05% [50 mcg/spray] (15 mL) [contains benzalkonium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231195\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231246\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intranasal: Shake bottle well before each use. Prior to initial use, bottle should be primed until a fine spray is delivered. Instruct patients to blow nose and clear nasal passages before administering spray and to inhale nasally while spraying.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231190\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergic rhinitis:</b> Symptomatic treatment of allergic rhinitis in patients 12 years and older.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231184\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levocabastine may be confused with levobunolol, levOCARNitine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Livostin may be confused with lovastatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Livostin [Canada and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]; Lovastin brand name for lovastatin [Malaysia, Poland, Singapore]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231197\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Most adverse reactions are transient. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site burning, application site irritation, application site pain, application site reaction (dryness, discomfort)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye irritation (3%; mostly with concomitant levocabastine eye drop administration) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (1%), pharyngolaryngeal pain, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis, application site reactions (nasal edema), bronchospasm, cough, dry nose, dysgeusia, dyspnea, eyelid edema, facial edema, hearing loss, hypersensitivity, increased appetite, malaise, nasal congestion, nasal obstruction (aggravated), nausea, palpitations, pruritus of ear (external), pruritus of nose, respiratory tract disease, rhinorrhea, skin rash, tachycardia, throat irritation, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231193\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to levocabastine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231194\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution; limited data available regarding use in this population.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299588\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11304611\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16009&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies when using oral doses much larger than the equivalent maximum human nasal dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231192\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Following intranasal application, minute amounts of levocabastine have been detected in human breast milk (Simons 1999). The manufacturer recommends that caution be exercised when administering levocabastine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231244\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent, selective histamine H<sub>1</sub>-receptor antagonist</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11231204\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 1.13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~55%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (minimal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 60% to 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 35 to 40 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (65% to 70% as unchanged drug); feces (10% to 20% as unchanged drug) (Simons, 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13733203\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bilina (ES);</li>\n      <li>Livocab (DE, NL);</li>\n      <li>Livostin (AE, AT, AU, BE, CH, CN, CZ, DK, EG, FI, GR, IL, IS, JP, KR, LB, LU, NO, NZ, PT, QA, SE, SI, VE, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Livostin (levocabastine) [product monograph]. Toronto, Ontario, Canada: Janssen Inc: July 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levocabastine-nasal-united-states-not-available-drug-information/abstract-text/10088031/pubmed\" target=\"_blank\" id=\"10088031\">10088031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FER and Simons KJ, &ldquo;Clinical Pharmacology of New Histamine H<sub>1</sub> Receptor Antagonists,&rdquo; <i>Clin Pharmacokinet</i>, 1999, 36(5):329-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levocabastine-nasal-united-states-not-available-drug-information/abstract-text/10384858/pubmed\" target=\"_blank\" id=\"10384858\">10384858</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16009 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11231185\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11231189\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11231227\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990765\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987916\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F11231226\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11231248\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11231195\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11231246\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11231190\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11231184\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11231197\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11231193\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11231194\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299588\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11304611\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11231191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11231192\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11231244\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11231204\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13733203\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16009|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levocabastine-nasal-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Levocabastine (Nasal) (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}